A. E. Eskazan Et Al. , "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.," Leukemia research , vol.38, no.7, pp.781-7, 2014
Eskazan, A. E. Et Al. 2014. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.. Leukemia research , vol.38, no.7 , 781-7.
Eskazan, A. E., Eyice, D., Kurt, E. A., Elverdi, T., Yalniz, F. F., Salihoglu, A., ... Ar, M. C.(2014). Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.. Leukemia research , vol.38, no.7, 781-7.
Eskazan, Ahmet Et Al. "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.," Leukemia research , vol.38, no.7, 781-7, 2014
Eskazan, Ahmet E. Et Al. "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.." Leukemia research , vol.38, no.7, pp.781-7, 2014
Eskazan, A. E. Et Al. (2014) . "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.." Leukemia research , vol.38, no.7, pp.781-7.
@article{article, author={Ahmet Emre EŞKAZAN Et Al. }, title={Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.}, journal={Leukemia research}, year=2014, pages={781-7} }